Intravitreous bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: Short-term results

Eye

Volumn 23, Issue 2, 2009, Pages 334-338

  Ruiz Moreno, J M ^a,b,d   Gomez Ulla, F ^c   Montero, J A ^b   Ares, S ^c   Lopez Lopez, F ^c   Rodriguez, M ^c   Fernandez, M ^c  

^a UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

^b Alicante   (Spain)

^c UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^d MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

Author keywords

Bevacizumab; Choroidal neovascularization; High myopia; Intravitreal injection

Indexed keywords

BEVACIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HIGH MYOPIA; HUMAN; MALE; OPTICAL COHERENCE TOMOGRAPHY; OPTICAL TOMOGRAPHY; PHOTODYNAMIC THERAPY; PILOT STUDY; RETINA FOVEA; SAFETY; SEX RATIO; SUBRETINAL NEOVASCULARIZATION; THICKNESS; VISUAL ACUITY; CHOROIDAL NEOVASCULARIZATION; CLINICAL TRIAL; COMPLICATION; DEGENERATIVE MYOPIA; INTRAOCULAR DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; TREATMENT OUTCOME; VERY ELDERLY; VITREOUS BODY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROIDAL NEOVASCULARIZATION; FEMALE; HUMANS; INJECTIONS, INTRAOCULAR; MALE; MIDDLE AGED; MYOPIA, DEGENERATIVE; PILOT PROJECTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS BODY;

EID: 60149091354     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/sj.eye.6703052     Document Type: Article

References (27)

1. Cohen SY, Laroche A, Leguen Y, Soubrane G, Coscas GJ. Etiology of choroidal neovascularization in young patients. Ophthalmology 1996; 103: 1241-1244.
2. Ruiz-Moreno JM, Montero JA. Long-term visual acuity after argon green laser photocoagulation of juxtafoveal choroidal neovascularization in highly myopic eyes. Eur J Ophthalmol 2002; 12: 117-122.
3. Secretan M, Kuhn D, Soubrane G, Coscas G. Long-term visual outcome of choroidal neovascularization in pathologic myopia: natural history and laser treatment. Eur J Ophthalmol 1997; 7: 307-316.
4. Cekic O, Ohji M, Fujikado T, Fang XY, Hayashi A, Kusaka S et al. Foveal translocation surgery and myopic subfoveal CNV membrane. Ophthalmology 2000; 107: 2117.
5. Uemura A, Thomas MA. Subretinal surgery for choroidal neovascularization in patients with high myopia. Arch Ophthalmol 2000; 118: 344-350.
6. Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin 1-year results of a randomized clinical trial-VIP report no. 1. Ophthalmology 2001; 108: 841-852.
7. Montero JA, Ruiz-Moreno JM. Verteporfin photodynamic therapy in highly myopic subfoveal choroidal neovascularisation. Br J Ophthalmol 2003; 87: 173-176.
8. Ruiz-Moreno JM, Montero JA. Subretinal fibrosis after photodynamic therapy in subfoveal choroidal neovascularisation in highly myopic eyes. Br J Ophthalmol 2003; 87: 856-859.
9. Chan WM, Lai TY, Wong AL, Liu DT, Lam DS. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study. Br J Ophthalmol 2007; 91: 174-179.
10. Montero JA, Ruiz-Moreno JM. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study. Br J Ophthalmol 2007; 91: 131-133.
11. Yamamoto I, Rogers AH, Reichel E, Yates PA, Duker JS. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia. Br J Ophthalmol 2007; 91: 157-160.
12. Sakaguchi H, Ikuno Y, Gomi F, Kamei M, Sawa M, Tsujikawa M et al. Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia. Br J Ophthalmol 2007; 91: 161-165.
13. Mandal S, Venkatesh P, Sampangi R, Garg S. Intravitreal bevacizumab (Avastin) as primary treatment for myopic choroidal neovascularization. Eur J Ophthalmol 2007; 17: 620-626.
14. Hernandez-Rojas ML, Quiroz-Mercado H, Dalma-Weiszhausz J, Fromow-Guerra J, Amaya-Espinosa A, Solis-Vivanco A et al. Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia. Retina 2007; 27: 707-712.
15. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization six-month results of a prospective pilot study. Ophthalmology 2007; June 26; [e-pub ahead of print].
16. Yamamoto I, Rogers AH, Reichel E, Yates P, Duker JS. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularization secondary to pathologic myopia. Br J Ophthalmol 2007; 91: 157-160.
17. Tewari A, Dhalla MS, Apte RS. Intravitreal bevacizumab for treatment of choroidal neovascularization in pathologic myopia. Retina 2006; 26: 1093-1094.
18. Sakaguchi H, Ikuno Y, Gomi F, Kamei M, Sawa M, Tsujikawa M et al. Intravitreal injection of bevacizumab for choroidal neovascularization caused by pathological myopia. Br J Ophthalmol 2007; 91: 161-165.
19. Laud K, Spaide RF, Freund KB, Slakter J, Klancnik JM, Jr. Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab. Retina 2006; 26: 960-963.
20. Nguyen QD, Shah S, Tatlipinar S, Do DV, Anden EV, Campochiaro PA. Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia. Br J Ophthalmol 2005; 89: 1368-1370.
21. Yoshida T, Ohno-Matsui K, Yasuzumi K, Kojima A, Shimada N, Futagami S et al. Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology 2003; 110: 1297-1305.
22. Tong JP, Chan WM, Liu DT, Lai TY, Choy KW, Pang CP et al. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol 2006; 141: 456-462.
23. Degenring RF, Jonas JB. Photodynamic therapy in combination with intravitreal triamcinolone for myopic choroidal neovascularization. Acta Ophthalmol Scand 2005; 83: 621.
24. Marticorena J, Gomez-Ulla F, Fernandez M, Pazos B, Rodriguez-Cid MJ, Sanchez-Salorio M. Combined photodynamic therapy and intravitreal triamcinolone acetonide for the treatment of myopic subfoveal choroidal neovascularization. Am J Ophthalmol 2006; 142: 335-337.
25. Wachtlin J, Behme T, Heimann H, Kellner U, Foerster MH. Concentric retinal pigment epithelium atrophy after a single photodynamic therapy. Graefes Arch Clin Exp Ophthalmol 2003; 241: 518-521.
26. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: phase III clinical trial results. Ophthalmol Clin North Am 2006; 19: 361-372.
27. Lynch SS, Cheng CM. Bevacizumab for neovascular ocular diseases. Ann Pharmacother 2007; 41: 614-625.